- CA$43.32m
- CA$66.25m
- CA$17.75m
- 13
- 52
- 36
- 24
Annual balance sheet for LSL Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2012 July 31st | 2021 July 31st | 2022 July 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.117 | 0 | 0 | 0.008 | 0.296 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.091 | 0.017 | 0.025 | 2.68 | 4.95 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.21 | 0.017 | 0.026 | 7.2 | 15.4 |
| Net Property, Plant And Equipment | 0.002 | — | — | 14.7 | 22.9 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 1.16 | 0.017 | 0.026 | 30.9 | 53.5 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.08 | 0.203 | 0.285 | 15.1 | 9.65 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Liabilities | 0.08 | 0.203 | 0.285 | 22.2 | 28.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.08 | -0.186 | -0.26 | 8.65 | 24.9 |
| Total Liabilities & Shareholders' Equity | 1.16 | 0.017 | 0.026 | 30.9 | 53.5 |
| Total Common Shares Outstanding |